Szpital Specjalistyczny W Prabutach Sp. z o.o. — Clinical Trial Site

25 Registered trials

14 Currently recruiting

Organisation

Szpital Specjalistyczny W Prabutach Sp. z o.o.

Location

Prabuty, Poland

Identifier

ORG-100047017

Address

Ul. Kuracyjna 30, 82-550, Poland

Departments

n/a
Oddzia Pulmonologii
Oddzial Pulmonologii
Oddzial Pulmunologii
Oddział Onkologii Klinicznej
Oddział Pulmonologii
Oddział Pulmunologii
Oncology
Szpital Specjalistyczny Prabuty, Oddział Pulmunologii

Clinical trials at this site (25)

Search interface

A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-sm… Recruiting

2024-515853-48-00 advanced/metastatic non-squamous non-small cell lung ca 5 2025-09-05
A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici… Recruiting

2024-516792-32-01 Metastatic non-squamous non-small cell lung cancer 4 2025-07-18
A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer Recruiting

2024-514048-98-00 Previously Untreated Metastatic Non-Squamous Non-Small 5 2025-01-30
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Limited-Stage Small-Cell Lung Cancer (LS SCLC) 5 2024-11-07
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag… Recruiting

2024-520164-33-00 Non-Small Cell Lung Cancer 5 2025-12-09
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant… Recruiting

2024-516794-70-00 Metastatic non-squamous non-small cell lung cancer 4 2025-11-03
A Study of Navlimetostat (BMS986504) in Participants with Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer with Homozygous MTAP… Recruiting

2024-519814-29-00 Advanced or Metastatic Non-small Cell Lung Cancer 4 2025-09-12
A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s… Recruiting

2024-513682-40-01 Non-squamous (NSQ), Stage IV or Recurrent Non-small Cel 5 2025-07-04
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
HARMONi-3 Recruiting

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
Study of pre- and post-surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) Recruiting

2023-507778-42-00 Non-Small Cell Lung Cancer II, III 4 2023-03-08
A Study of Subcutaneous Nivolumab plus Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recur… Ended

2024-520108-25-00 Non-small cell lung cancer (NSCLC) 4 2025-11-05
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended

2024-515740-23-00 Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-03-25
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Extensive-stage small-cell lung cancer 5 2022-04-01
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung… Ended

2024-513770-22-00 Malignant Solid Tumors - Non Small Cell Lung Cancer 4 2021-09-22
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Ended

2023-509059-15-00 Malignant solid tumors: endometrial carcinoma (EC), uro 7 2019-04-30
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENT… Ended

2023-510446-24-00 Cancer cachexia 4 2023-05-30
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19